Key clinical point: The first randomized trial to see if a short course of a direct-acting antiviral works as well for acute HCV infection as the standard 12-week course was stopped early.
Major finding: The relapse rate was 9.7% among 93 people randomized to 6 weeks of sofosbuvir-velpatasvir (Epclusa) versus 2% among 99 subjects randomized to the standard 12-week course.
Study details: Randomized international trial with 192 participants
Disclosures: The National Institutes of Health funded the work. The lead investigator disclosed institutional research grants from Abbvie and Gilead, maker of Epclusa.
Matthews G. CROI 2020 abstract 121.